about
Mutations in cytokine receptor-like factor 1 (CRLF1) account for both Crisponi and cold-induced sweating syndromesResveratrol and MyopathySuccinate dehydrogenase deficiency in humanCarnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspectsTranscriptional regulation by glucocorticoids of mitochondrial oxidative enzyme genes in the developing rat kidneyCombination of lipid metabolism alterations and their sensitivity to inflammatory cytokines in human lipin-1-deficient myoblastsThromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome).Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapyA gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.Organization of the human liver carnitine palmitoyltransferase 1 gene ( CPT1A) and identification of novel mutations in hypoketotic hypoglycaemia.Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation.Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate.GSH monoethyl ester rescues mitochondrial defects in cystic fibrosis models.Resveratrol attenuates oxidative stress in mitochondrial Complex I deficiency: Involvement of SIRT3.Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts.Fluxes of nicotinamide adenine dinucleotides through mitochondrial membranes in human cultured cells.Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.Dietary lipids regulate beta-oxidation enzyme gene expression in the developing rat kidney.Beneficial effects of resveratrol on respiratory chain defects in patients' fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling.Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.Characterization of fatty acid oxidation in human muscle mitochondria and myoblasts.Bezafibrate for an inborn mitochondrial beta-oxidation defect.Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase.Mitochondrial biogenesis and development of respiratory chain enzymes in kidney cells: role of glucocorticoids.A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy.Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders.Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?Potential of fibrates in the treatment of fatty acid oxidation disorders: Revival of classical drugs?La β-oxydation mitochondriale des acides gras : une voie métabolique essentielle du fonctionnement musculaireMitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies.Lack of control by adrenal steroids of oxidative enzymes and Na/K-ATPase development in the rat proximal tubuleEffect of glucocorticoids on mitochondrial oxidative enzyme and Na-K-ATPase activities in the rat proximal tubule and thick ascending limb of HenleRegulation of fatty acid transport protein and mitochondrial and peroxisomal beta-oxidation gene expression by fatty acids in developing ratsBirth-related changes in energy metabolism enzymes and Na-K-ATPase in kidney proximal convoluted tubule cellsThe role of PPAR alpha as a "lipostat" transcription factorFatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alphaThe role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolismExposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts
P50
Q24682847-DB6DAFFF-4E5B-4F6F-8A71-D82FDDDD19B2Q26748160-F9207AD1-1E06-47E8-BE05-9D5103A5ACD8Q28270821-561DC575-BA36-4093-87FC-4EB4A8830698Q28281779-A326CBED-A7EF-45EE-A48B-A5FF313FE2A7Q28570684-1304D34F-0154-4818-A8DC-05BEF9CF5542Q33554610-D31504E4-B3A2-4FE6-A567-03B920084BC1Q34748761-D8277F57-F198-4F76-A7F9-429FD693864FQ36512079-97F0EA48-494F-4E55-ACB3-AF1EA439653EQ37387371-93630CD6-E16B-4C8C-B669-373D58B43EB8Q38363595-217DC592-78A2-45ED-94C8-FBE93B9C68C3Q38550350-75477966-1509-41AA-BF2F-E48E1FAD2243Q38860352-546CD343-AD17-4F09-AEF9-10B3089743CDQ39553353-A407136E-F8E9-4783-B1E5-F1A48B2D7D48Q39811609-6A2A05EC-AF5C-4C2B-8074-B02906D692DFQ40528109-0170C90F-25B8-42AF-A54F-419E3151B6A5Q41190867-BC3692F2-6475-4D42-9F42-4DB794BC805EQ42163665-AB83B6A1-DADA-44FD-BEDC-1FB52A6F1B64Q42538296-DBF56F1E-1355-4102-AE0A-3A730F777DBDQ42707781-D5BFFBFE-AEC3-4E1C-868D-82C8A45C2309Q43053414-C47BA973-750A-40C4-BEA3-AEC9744B9177Q44345949-4792EF38-7A9F-45C8-B53A-CC5851263CDAQ46116658-748615D3-8E75-4C5E-A737-C2B958D0356AQ46663603-C1693A99-BAA3-4462-9D24-7F5ADBC452C8Q50679387-5E7DD9B4-B466-46E4-B1D1-F64BEDB55507Q52215771-A363CEF7-842A-49B5-BF24-A19719D8F022Q54479172-2DF16B5B-6AFB-4B8A-8EAD-B09636F753E7Q54544721-017A7ED3-3B5A-4068-B1CF-84376AABED5DQ56241293-2EC28DCB-5A98-4C9B-8B1E-525DCD192AA5Q56241304-6C055558-6F90-41BD-ADBC-635F7B7A17CCQ56241311-D636D3A1-CB21-4C02-B029-C5FE7C1980E1Q64943955-9D966721-AE64-449F-81DB-910570463D34Q70516973-67304E6B-CFEF-4733-B70B-41B90F9687B2Q72104942-F1474D7F-DA63-4AE5-BF70-BAE62F7B63CBQ73108900-399298F4-1340-4AF6-BCA1-E1108D1E1DDFQ73281916-7FAB0D99-D237-4C5B-BDA4-9BF70BFDDE1FQ73530134-EEFFB7CE-B73E-448E-8ABD-9AA9EF66D6CDQ77195358-B934005D-A33B-4B30-95C2-656536738770Q78202069-BE7F4A2C-807E-4CEB-BF4F-64F7E7AF19ACQ83541244-44578058-D8BF-45EB-A1E2-A67B71526571
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fatima Djouadi
@en
Fatima Djouadi
@es
Fatima Djouadi
@nl
Fatima Djouadi
@sl
type
label
Fatima Djouadi
@en
Fatima Djouadi
@es
Fatima Djouadi
@nl
Fatima Djouadi
@sl
prefLabel
Fatima Djouadi
@en
Fatima Djouadi
@es
Fatima Djouadi
@nl
Fatima Djouadi
@sl
P106
P21
P31
P496
0000-0003-0350-0935